High-grade B-cell Lymphoma Not Otherwise Specified

• CLINICAL_TRIALS research · 2026-04-23
  Clinical Trial Update: Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 2]

  A Phase 2 clinical trial update evaluating epcoritamab in combination with dose-adjusted EPOCH-R for aggressive B-cell non-Hodgkin lymphoma;…

• CLINICAL_TRIALS research · 2026-03-03
  Clinical Trial Update: Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma [Phase 1]

  Phase 1 trial evaluating polatuzumab vedotin with chemotherapy, with or without glofitamab, for untreated aggressive large B-cell lymphoma. …

• CLINICAL_TRIALS research · 2026-02-19
  Clinical Trial Update: Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  This clinical trial update reports ongoing Phase 1/2 testing of the combination epcoritamab plus ibrutinib for relapsed or refractory aggres…

• CLINICAL_TRIALS research · 2026-02-06
  Clinical Trial Update: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 2]

  Ongoing Phase 2 trial evaluating nivolumab in combination with DA-REPOCH chemotherapy for aggressive B-cell non-Hodgkin lymphomas, including…

• CLINICAL_TRIALS research · 2025-06-13
  Clinical Trial Update: Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma [Phase 1]

  Phase 1 clinical trial evaluating C402-CD19-CAR for relapsed or refractory B-cell lymphomas is currently recruiting.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.